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Background/aim: Extraskeletal myxoid chondrosarcoma (EMC) is a rare soft tissue sarcoma. The aim of this study is to present the
results of the patients we treated with the diagnosis of EMC as an oncology reference center.
Materials and methods: Information on 13 patients diagnosed with EMC between 2006 and 2018 was retrospectively reviewed. Patients’
demographic information, tumor sizes, surgical treatments, chemotherapy and radiotherapy statuses, follow-up times, recurrences, and
metastases were recorded.
Results: Mean patient age was 53.6 ± 15 years (range: 28-73). In 8 patients, the tumor was located in the lower limbs, most commonly
in the thigh (46.2%). Mean follow-up period was 52.8 ± 19.9 (24-96) months. All patients underwent wide resections and only one
had a positive surgical margin. In follow-up, 5 (38.5%) patients experienced recurrence; 6 patients had lung metastasis (46.2%) and 7
patients (53.8%) died. Mean tumor size was 10.4 ± 3.2 (5-17) cm. Median survival time was 61 (50.5-71.4) months and 5-year survival
rate was 51.8%. There was no significant difference between survival times according to age, gender, side, limb location, postoperative
radiotherapy, recurrence, or presence of lung metastasis. The cut-off value for death obtained by ROC analysis of tumor size was 11 cm.
Conclusion: EMC is a rare soft tissue sarcoma with high local recurrence and metastasis capacity. Tumor size and metastatic disease are
poor prognostic criteria. If it is a localized disease, the first option should be wide resection.
Key words: Extraskeletal, chondrosarcoma, recurrence, metastasis, tumor

1. Introduction
Extraskeletal myxoid chondrosarcoma (EMC) is a rare
soft tissue sarcoma that accounts for 2.5% to 3% of all soft
tissue sarcomas. EMC is characterized by a multinodular
architecture, myxoid matrix, and malignant chondroblasts
[1,2]. Enzinger and Shiraki were the first to describe it in
1972, and it was accepted as a low-grade lesion in the first
years due to its histological appearance [3]. In the following
years, Oliveira et al. [4] defined EMC as a separate sarcoma
of chondroblastic origin originating from extraskeletal soft
tissues. However, there is no consensus in the literature
regarding the histopathogenesis of EMC, and EMC is
currently classified as a vague differentiation tumor in the
revised version of the World Health Organization (WHO)
Classification of Tumours of Soft Tissue and Bone [5].
Furthermore, a definitive distinction from other myxoid
tumors is difficult because EMC has no pathognomonic

clinical, imaging, or pathological characteristics. EMC is
often found in the proximal extremities of middle-aged men
and is usually asymptomatic; it has a slow course but a high
tendency for local recurrence and metastasis [6]. Although
their course is slow, these tumors have a significant risk of
eventual relapse and metastasis, especially for the lungs.
The current approach in the treatment of EMC is primarily
surgical treatment if the disease is localized, and radiotherapy
if necessary. If the disease is advanced rather than localized,
antiangiogenic agents, besides standard chemotherapy, have
recently shown promising activity. Although the expected
recurrence risk is approximately 50%, it is the prolongation
of the desired life expectancy [7]. Because of the very low
incidence, there are no clinical studies investigating the best
treatment options for these tumors. The aim of this study
is to present the results of the patients we treated with the
diagnosis of EMC as an oncology reference center.
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2. Materials and methods
The data of 13 patients diagnosed with EMC in our
clinic between January 2006 and January 2018 were
retrospectively reviewed. Demographic information, tumor
sizes, surgical treatments, chemotherapy and radiotherapy
statuses, follow-up periods, recurrences, and metastases
of the patients were recorded. Histopathologically, EMC
is characterized by abundant hypocellular myxoid matrix
and interconnected cords of uniform neoplastic cells with
a common spindle cell differentiation. Patients whose
diagnosis of EMC was confirmed histopathologically were
included in the study (different immunohistochemical
images of EMC Figures 1A–1C). For the patients whose
diagnosis of EMC was confirmed, a multidisciplinary
decision was made in the tumor council of our hospital
in accordance with the current treatment principle, and
the treatment option (surgical treatment, chemotherapy,
and radiotherapy) was decided. Patients whose diagnosis
could not be established pathologically and whose file
information could not be obtained were excluded from the
study. The study protocol was approved by the institutional
review board of Dr Abdurrahman Yurtaslan Oncology
Hospital (2020/103).
2.1. Statistical analyses
Statistical analyses were performed using IBM SPSS
Statistics for Windows, version 22.0 (IBM Corp., Armonk,
NY, USA). Descriptive statistics were presented as numbers
and percentages for categorical variables and as mean ±
standard deviation and median (minimum–maximum
values) for continuous variables. Prognostic values of
tumor size were assessed using receiver operating curve
(ROC) analysis. The area under the ROC curve (AUC)
results were considered excellent for AUC values of 0.9–1,
good for AUC values of 0.8–0.9, fair for AUC values of
0.7–0.8, poor for AUC values of 0.6–0.7, and failed for
AUC values of 0.5–0.6. Following ROC analysis, AUC and

cut-off values, sensitivity and specificity of those cut-off
values, likelihood ratios, and positive predictive values
and negative predictive values were presented. Survival
analyses were performed with the Kaplan–Meier method
and log-rank test. Values of p < 0.05 were considered
statistically significant [8,9].
3. Results
Thirteen patients diagnosed with EMC with a mean age
of 53.6 ± 15 (range: 28 to 73) years were included in this
study (Table 1). In 8 of the patients, the tumor was located
in the lower limbs and the most common location in
the lower extremities was the thigh (46.2%). The mean
follow-up period of the patients was 52.8 ± 19.9 (range:
24 to 96) months. Wide resection was performed in all
patients and only 1 patient had a positive surgical margin.
While recurrence developed in 5 (38.5%) of the patients
during follow-up, lung metastasis (46.2%) was detected in
6 patients, and 7 patients (53.8%) died due to the disease
and complications related to the disease. The average
tumor size was determined as 10.4 ± 3.2 (range: 5 to 17)
cm (Table 2).
The median survival time of the patients in the study
was 61 (range: 50.5–71.4) months. The 5-year survival
rate was 51.8%. It was found that there was no significant
difference between survival times according to age,
sex, side, extremity location, receiving postoperative
radiotherapy, recurrence, and presence of lung metastasis
(log-rank tests: p > 0.05) (Table 3). The cut-off value for
death obtained by ROC analysis of the tumor size was 11
cm (Figure 2). Accordingly, it was observed that the survival
times of patients with a tumor size of ≥11 were statistically
significantly shorter (log-rank test: p = 0.014) (Figure 3). It
was also determined that the survival times of patients who
received postoperative chemotherapy (metastatic patients)
were significantly shorter than those of patients who did
not (log-rank test: p = 0.024) (Figure 4).

Figure 1. A) Combined view of undifferentiated areas of hyaline cartilage and small cells in the tumor (magnification 100×, H&E); B)
Small undifferentiated cell component (magnification 400×, H&E); C) Immunohistochemical S100 positivity in cartilaginous areas
(magnification 200×).
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Table 1. Information about patients.
No

Age

Localization

Tumor size, cm

Surgical border

RT
CT

Recurrence

Lung metastasis

Follow-up time
(n)

1

53

Elbow

5

-

RT

-

-

86

2

74

Elbow

12

+

RT

+

-

27

3

28

Shoulder

11

-

RT

-

-

19

4

62

Shoulder

8

-

RT,CT

+

+

42

Ex

5

66

Wrist

11

-

CT

-

+

14

Ex

6

44

Cruris

14

-

CT

+

+

32

Ex

7

43

Cruris

9

-

-

+

-

37

8

52

Thigh

17

-

CT

-

+

46

9

58

Thigh

7

-

RT

-

-

42

10

67

Thigh

9

-

RT

+

-

47

11

34

Thigh

13

-

CT

-

+

51

12

41

Thigh

10

-

-

-

-

39

13

75

Thigh

9

-

-

-

+

74

Exitus
Ex

Ex

Ex
Ex

RT: radiotherapy; CT: chemotherapy n: month
ROC Curve for Tumor Size

1.0

1.0

0.8

0.8

Cum Survival

0.6

0.4

0.2

0.0

0.6

0.4

0.2

0.2

0.4

0.6

0.0

1.0

0.8

20.00

1- Specificity

40.00

60.00

80.00

100.00

Months

Figure 2. Receiver operating characteristic (ROC)
curves for tumor size (PPV: positive predictive
value, NPV: negative predictive value).

Figure 3. OS curve of patients according to tumor
size groups.

1.0

0.8

0.6

0.4

0.2

0.0
0.00

20.00

40.00

60.00

80.00

100.00

Figure 4. OS curve of patients according to CT
groups.
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Table 2. Baseline data of malignancies.
Characteristics
Sex, n (%)
Female
Male
Age, years
Mean ± SD
Median(min–max)
Side, n (%)
Right
Left
Extremity, n (%)
Upper
Lower
Localization, n (%)
Thigh
Cruris
Shoulder
Elbow
Wrist
Follow-up time, months
Mean ± SD
Median(min–max)
Tumor size, cm
Mean ± SD
Median (min–max)
Exitus, n (%)
Yes
No
Surgical treatment, n (%)
Wide resection
Surgical margin, n (%)
Positive
Negative
Postoperative radiotherapy
Yes
No
Postoperative chemotherapy
Yes
No
Recurrence, n (%)
Yes*
No
Lung metastasis
Yes
No

Total N = 13
5 (38.5)
8 (61.5)
53.6 ± 15
53 (28–75)
6 (46.2)
7 (53.8)
5 (38.5)
8 (61.5)
6 (46.2)
2 (15.4)
2 (15.4)
2 (15.4)
1 (7.7)
52.8 ± 19.9
52 (24–96)
10.4 ± 3.2
10 (5–17)
7 (53.8)
6 (46.2)
13 (100)
1 (7.7)
12 (92.3)
6 (46.2)
7 (53.8)
5 (38.5)
8 (61.5)
5 (38.5)
8 (61.5)
6 (46.2)
7 (53.8)

*Recurrence surgery: 2 patients underwent wide resection, 3 patients underwent amputation
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Table 3. Overall survival rates according to selected variables.
Total

Log-rank test

Overall survival, months,

N = 13

p

Median (95% CI)

3-year survival rate, %

5-year survival rate, %

61 (50.5–71.4)

92.3

51.8

Female

61 (32.6–89.4)

100

75

Male

56 (47.5–64.5)

87.5

56.3

56 (35.7–76.4)

100

40

84 (35.1–132.9)

85.7

57.1

Right

52 (28.9–75.1)

83.3

31.3

Left

61 (53.6–68.6)

100

64.3

Upper

52 (28.8–75.2)

80.0

26.7

Lower

61 (53.4–68.6)

100

65.6

84 (37.4–130.5)

100

80

42 (31.6–52.4)

83.3

20.8

Yes

75 (52.9–97.9)

100

60

No

56 (38.4–73.6)

85.7

47.6

52 (30.5–73.4)

80

20

84 (17.3–150.7)

100

85.7

Yes

52 (36.4–67.6)

100

30

No

61 (50.8–71.1)

87.5

43.8

Yes

52 (35.2–68.8)

83.3

33.3

No

86 (68.5–103.7)

100

83.3

All patients
Sex

Age

0.911

0.635

<53 (median age)
≥53
Side

Extremity

0.653

0.491

Tumor size
<11 cm
≥11 cm

0.014

Radiotherapy

0.389

Chemotherapy

0.024

Yes
No
Recurrence

Lung metastasis

0.222

0.085

4. Discussion
EMC is a rare soft tissue tumor that occurs twice as often
in males than in females in the extremities of middle-aged
adults [10]. The staging system of the French Federation of
Cancer Centers (FNCLCC) lists EMC as a stage 2/3 tumor
[11]. Our knowledge about tumor molecular features has
increased in recent years; it is now known that it harbors
the tumor translocation (9; 22) (q22; q11) and results in
the EWSR1/NR4A3 sequence in most patients [5,12].
Other translocations have also been identified. The main
finding of this study is that EMC is a rare malignant soft
tissue sarcoma with high recurrence and lung metastasis
capacity. In addition, metastasis and tumor size are poor
prognostic factors.

Since EMC has no distinctive clinical features, its
differential diagnosis is difficult and it may be confused
with other myxoid soft tissue sarcomas, such as
myxofibrosarcoma, myxoid liposarcoma, and metastatic
carcinomas, including myoepithelial tumors and
neuroendocrine tumors. Usually the tumor presents as a
single slow-growing soft tissue lesion, about 5-10 cm in
diameter [1]. With computed tomography, EMCs appear
as soft tissue masses with lobular contours [1]. Oliveria et
al. [4] presented the results of 23 EMC cases at the Mayo
Clinic in 2000; the mean tumor size of the patients with
a mean age of 50 was 9.5 cm and tumors were located in
the lower extremities in 83% of the patients. In addition,
Oliveria et al. [4] showed that tumor sizes greater than
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10 cm had worse prognosis. Similarly, Mcgrory et al. [13]
said that tumor size is a poor prognostic factor. In our
study, conducted with 13 EMC patients with a mean age
of 53.6, tumors were most frequently located in the lower
extremities (61.5%) and the mean tumor size was 10.4 cm.
Tumor sizes above 11 cm were found to be associated with
mortality.
Since EMCs are rare tumors, our knowledge about this
disease is limited, making it difficult to draw definitive
conclusions about the clinical features, prognostic factors,
and appropriate treatment of the tumors. Initially, it was
considered by Enzinger and Shiraki as a low-grade sarcoma
according to the initial definition of the tumor, and only 4
out of 34 patients were reported to have died of the disease
in short-term follow-up (median: 3.5 years) [3]. Later,
Saleh et al. [14] showed that EMC was a destructive tumor
with high local recurrence and metastasis capacity among
the 10 EMC patients they followed. Similarly, Ogura et al.
[15] found 31% recurrence and 50% lung metastasis in the
22 EMC patients they followed. Likewise, we found high
rates of local recurrence (38.5%) and metastasis (46.2%) in
13 patients followed by EMC.
Despite its high recurrence and metastasis rates, there
are publications in the literature showing that EMC is
a slow-progressing sarcoma with 5-year survival rates
between 70% and 100% [4, 12, 13]. Our 5-year survival
rate (51.8%) contradicts the findings in the literature. We
attribute this to our encounter with an advanced patient
group rather than a localized disease, since we are an
oncology reference center in our country.
EMC has limited response to chemotherapy; neither
single nor combined chemotherapeutic agents showed
statistically significant results in treating EMC and more

research for identifying novel target therapies is therefore
necessary [12]. In addition, the current approach does
not recommend chemotherapy in localized disease.
Therefore, the group receiving chemotherapy is the group
with advanced disease with a lower life expectancy [7].
Similarly, in our study, there was no positive contribution
to the life expectancy of patients receiving postoperative
chemotherapy.
This study has some limitations. Firstly, it is a singlecenter retrospective study. In addition, the number of
patients was small because EMC is a rare tumor. Not
checking scores for functional outcomes was another
limitation. All the same, this study is valuable due to the
limited number of publications on the surgical and clinical
results of EMC.
5. Conclusion
EMC is a rare soft tissue sarcoma with high local recurrence
and metastasis capacity. Tumor size and metastatic disease
are poor prognostic criteria. If it is a localized disease, the
first option should be wide resection.
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